Researchers develop a deep learning framework to accelerate ultra-low-field brain MRI, achieving faster scan times and enhanced image quality. The method shows promise in making MRI more accessible and reliable, especially in settings with limited access to high-field scanners.
Cybin Scores Breakthrough Therapy Designation for Deuterated Psilocybin Analog in MDD, Shares 4-Month Data – Psychedelic Alpha
Today, psychedelic drug developer Cybin announced that it has received breakthrough therapy designation for CYB003, its deuterated psilocybin analog candidate under development for major depressive
March 13, 2024